Arbutus Biopharma Corp (NASDAQ: ABUS)’s stock price has increased by 15.87 compared to its previous closing price of 2.52. However, the company has seen a 17.27% increase in its stock price over the last five trading sessions. Reuters reported 2024-04-03 that Shares of Moderna fell 4% on Wednesday after a U.S. judge issued an order that strengthened Arbutus’ arguments in a patent infringement lawsuit related to Moderna’s blockbuster COVID-19 vaccines.
Is It Worth Investing in Arbutus Biopharma Corp (NASDAQ: ABUS) Right Now?
Additionally, the 36-month beta value for ABUS is 2.09. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for ABUS is 134.01M and currently, short sellers hold a 3.08% ratio of that float. The average trading volume of ABUS on April 04, 2024 was 938.77K shares.
ABUS’s Market Performance
ABUS stock saw an increase of 17.27% in the past week, with a monthly gain of 7.75% and a quarterly increase of 12.74%. The volatility ratio for the week is 10.63%, and the volatility levels for the last 30 days are 5.01% for Arbutus Biopharma Corp (ABUS). The simple moving average for the last 20 days is 12.18% for ABUS stock, with a simple moving average of 31.40% for the last 200 days.
Analysts’ Opinion of ABUS
Many brokerage firms have already submitted their reports for ABUS stocks, with Jefferies repeating the rating for ABUS by listing it as a “Buy.” The predicted price for ABUS in the upcoming period, according to Jefferies is $5 based on the research report published on February 02, 2022 of the previous year 2022.
Jefferies, on the other hand, stated in their research note that they expect to see ABUS reach a price target of $5. The rating they have provided for ABUS stocks is “Hold” according to the report published on February 25th, 2021.
H.C. Wainwright gave a rating of “Buy” to ABUS, setting the target price at $10 in the report published on December 17th of the previous year.
ABUS Trading at 10.77% from the 50-Day Moving Average
After a stumble in the market that brought ABUS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.41% of loss for the given period.
Volatility was left at 5.01%, however, over the last 30 days, the volatility rate increased by 10.63%, as shares surge +9.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +23.21% upper at present.
During the last 5 trading sessions, ABUS rose by +17.27%, which changed the moving average for the period of 200-days by +19.67% in comparison to the 20-day moving average, which settled at $2.62. In addition, Arbutus Biopharma Corp saw 16.80% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABUS starting from McElhaugh Michael J., who sale 10,164 shares at the price of $2.31 back on Feb 02 ’24. After this action, McElhaugh Michael J. now owns 1,504,793 shares of Arbutus Biopharma Corp, valued at $23,504 using the latest closing price.
Sofia Michael J., the Chief Scientific Officer of Arbutus Biopharma Corp, sale 9,982 shares at $2.31 during a trade that took place back on Feb 02 ’24, which means that Sofia Michael J. is holding 1,485,121 shares at $23,083 based on the most recent closing price.
Stock Fundamentals for ABUS
Current profitability levels for the company are sitting at:
- -4.29 for the present operating margin
- 0.92 for the gross margin
The net margin for Arbutus Biopharma Corp stands at -3.97. The total capital return value is set at -0.64. Equity return is now at value -59.99, with -42.88 for asset returns.
Based on Arbutus Biopharma Corp (ABUS), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -11.5. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -212.2.
Currently, EBITDA for the company is -76.63 million with net debt to EBITDA at 0.23. When we switch over and look at the enterprise to sales, we see a ratio of 27.92. The receivables turnover for the company is 7.64for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.87.
Conclusion
In conclusion, Arbutus Biopharma Corp (ABUS) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
